NASDAQ:ADMS Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.22▼$8.2250-Day Range$7.97▼$8.2352-Week Range$4.02▼$9.15VolumeN/AAverage Volume692,487 shsMarket Capitalization$376.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Adamas Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ADMS Stock News HeadlinesMay 13, 2024 | prnewswire.comGlancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMSApril 7, 2023 | benzinga.comSurvalent, Electroval win bid to provide ICE "first of its kind" ADMS and DERMS platformJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 7, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market 2023 | Global Industry Report Forecast 2029March 30, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market LATEST REPORT 2023 to 2030March 3, 2023 | investing.comAdamas One Corp (JEWL)March 1, 2023 | marketwatch.com2023 Advanced Distribution Management System (ADMS) Market: Top Growing Regions for Business Leaders by 2029March 1, 2023 | marketwatch.comAdvanced Distribution Management System (ADMS) Market 2023 | Global Industry Report Forecast 2029July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 24, 2023 | marketwatch.comAdvanced Distributed Management System (ADMS) Market Is Booming Worldwide Forecast 2023-2029January 14, 2023 | marketwatch.comAdvanced Distribution Management Systems (ADMS) Market Future Trends Demand 2023, and Forecast to 2029May 25, 2022 | insidermonkey.com8 Stocks to Buy According to Devesh Gandhi’s SilverArc CapitalNovember 24, 2021 | finance.yahoo.comSupernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsNovember 4, 2021 | finance.yahoo.comSupernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call TranscriptNovember 2, 2021 | finance.yahoo.comHow Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?November 1, 2021 | bizjournals.comEast Bay drug maker's potential sale brings lawsuits, job cutsOctober 28, 2021 | finance.yahoo.comWill Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should KnowOctober 27, 2021 | finance.yahoo.comADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the FirmSee More Headlines Receive ADMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADMS CUSIPN/A CIK1328143 Webwww.adamaspharma.com Phone(510) 450-3500Fax510-428-0519Employees138Year Founded2002Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,400,000.00 Net Margins-71.11% Pretax Margin-71.11% Return on EquityN/A Return on Assets-42.96% Debt Debt-to-Equity Ratio21.25 Current Ratio4.53 Quick Ratio4.17 Sales & Book Value Annual Sales$74.46 million Price / Sales5.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-17.49Miscellaneous Outstanding Shares45,787,000Free Float37,133,000Market Cap$376.37 million OptionableOptionable Beta2.82 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesNeil F. McFarlaneChief Executive Officer & DirectorChristopher B. PrentissChief Financial OfficerAdrian QuartelChief Medical OfficerVijay ShreedharChief Commercial OfficerJill M. JeneHead-Corporate Development & StrategyKey CompetitorsAytu BioPharmaNASDAQ:AYTUEvolusNASDAQ:EOLSBelite BioNASDAQ:BLTEIndiviorNASDAQ:INDVLongboard PharmaceuticalsNASDAQ:LBPHView All Competitors ADMS Stock Analysis - Frequently Asked Questions How were Adamas Pharmaceuticals' earnings last quarter? Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company had revenue of $25.90 million for the quarter, compared to analysts' expectations of $25.07 million. What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO? 2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adamas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). This page (NASDAQ:ADMS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamas Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adamas Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.